Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 21INDUSTRY 9NIH 3NETWORK 2UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Extrapancreatic Neuroendocrine Tumor 1

Interventions

S 1 (combination) 16Paclitaxel 11Oxaliplatin 10Capecitabine 10Cisplatin 7Irinotecan 6titanium silicide 5sintilimab 4nimotuzumab 4nedaplatin 4TP protocol 3HMPL-013 3Fluorouracil 3Bevacizumab 3130-nm albumin-bound paclitaxel 3toripalimab 2raltitrexed 2Trastuzumab 2Tegafur 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Adjuvant 2Radiosurgery 2Radiation 2Neoadjuvant Therapy 2Leucovorin 2Esophagectomy 2Docetaxel 2Chemotherapy, Adjuvant 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Temozolomide × Gastrointestinal × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡